• Faron stock falls on traumakine failure pharmatimes
    July 09, 2018
    Shares Finnish group Faron Pharmaceuticals were trading down more than 80 percent on the London Stock Exchange after its key drug traumakine failed in acute respiratory distress syndrome (ARDS).
PharmaSources Customer Service